CRSP - Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges | Benzinga
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.
Along with lovo-cel, Vertex Pharmaceuticals Inc/CRISPR Therapeutics AG's (NASDAQ: CRSP) sickle cell candidate exa-cel also has PDUFA dates in December.
The analyst initiated a Neutral rating and said lovo-cel serves a much larger market than is addressable by Bluebird Bio's two other gene therapies (Zynteglo and Skysona), but Bluebird Bio's financial outlook appears uncertain.
The opportunities for Zynteglo ...